NY-COTY
20.4.2020 20:43:06 CEST | Business Wire | Press release
Coty Inc. announced today that Calvin Klein fragrances has achieved a Material Health Certificate at the Silver level from the Cradle to Cradle Products Innovation Institute for Calvin Klein’s first clean and environmentally conscious fragrance, CK EVERYONE Eau de toilette.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200420005792/en/
Silver level material health certification indicates that 100% of the chemical substances in CK EVERYONE Eau de toilette have been assessed and are compliant with the Cradle to Cradle Certified Product Standard material health requirements at the Silver level. These achievements also serve as the foundation of a material health optimization strategy for further improving the environmental safety of the fragrance over time.
Simona Cattaneo, President of Luxury Brands at Coty, said: “We are proud of Coty’s first Cradle to Cradle Material Health certificate for CK EVERYONE Eau de toilette which demonstrates the positive impact of our Beauty That Lasts platform. The Material Health certificate reinforces Coty’s commitment to its sustainability platform, with the objective of building a better business while making a positive contribution towards societal, ethical and environmental change within the beauty industry.”
The Cradle to Cradle Certified™ Material Health Certificate offers a solution to growing industry and consumer interest in knowing more about the chemicals used in products across their supply chains and avoiding chemicals of concern. By using the rigorous, globally recognized material health assessment methodology of the Cradle to Cradle Certified Product Standard, the Material Health Certificate provides manufacturers with a trusted means of assessing, optimizing and verifying their product chemistries for safety and the environment. The material health evaluation of CK EVERYONE Eau de toilette was executed by MBDC, a third-party Cradle to Cradle accredited assessor.
“Achieving a Cradle to Cradle Material Health certificate for CK EVERYONE Eau de toilette is another positive step in moving the beauty industry towards the universal use of materials that are safe, circular and responsible,” said Dr. Christina Raab, Vice President of Strategy and Development for the Institute. “We look forward to Coty’s continued leadership as the company uses the Cradle to Cradle Certified Product Standard as a framework for improving the sustainability of this and other products.”
“We are thrilled to collaborate with Coty on their first Material Health Certificate for CK EVERYONE Eau de toilette,” said Jay Bolus, President of MBDC. “By obtaining a Material Health Certificate, they are communicating their commitment to transparency and that their fragrance is made with healthier materials. Coty is raising the bar for the beauty industry by insisting on product quality based on Cradle to Cradle Design™.”
About the Cradle to Cradle Products Innovation Institute
The Cradle to Cradle Products Innovation Institute is dedicated to powering innovation for the circular economy through products that have a positive impact on people and planet. Through the Cradle to Cradle Certified™ Products Program, the Institute sets the global standard for products that are safe, circular and made responsibly. Cradle to Cradle Certified is used by future-focused designers, brands, retailers and manufacturers across the value chain to innovate and optimize materials and products according to the world’s most advanced science-based measures for material health, product circularity, renewable energy and climate, water and soil stewardship, and social fairness.
The Institute also powers the global shift to a circular economy through partnerships and collaborative initiatives that equip businesses, governments and other stakeholders with the technical solutions and knowledge they need to innovate the way products are designed and made.
The Institute is headquartered in Oakland, California and Amsterdam, the Netherlands with offices in Washington DC. For more information, follow @c2ccertified or visit c2ccertified.org.
About MBDC
MBDC is a firm founded in 1995 by world-renowned architect William McDonough and chemist Dr. Michael Braungart. MBDC originated the Cradle to Cradle Design™ framework and the Cradle to Cradle Certified™ Products Program. MBDC leads companies to create a world of good by assessing product designs and integrating the framework into corporate strategy, communications, operations, and supply chains. Using the process of inventory, assessment and optimization, MBDC provides unique technical expertise to develop sustainable circular economy solutions around material health, material reutilization, renewable energy use, water stewardship and social fairness. MBDC partners with clients to provide scientific assessments and spur design innovation to create a world of good.
For additional information about MBDC, please visit www.mbdc.com
About CK EVERYONE
CK EVERYONE Eau de toilette is a clean and environmentally conscious fragrance, formulated with naturally derived ingredients, naturally derived alcohol, is vegan, recyclable, and is packaged with recycled materials.
CK EVERYONE Eau de toilette is a citrus fragrance that uplifts with zesty organic orange oil, a blue tea accord, and a vibrant cedarwood base creating the perfect combination of clean freshness, sweet sensuality and provocative edge. Master perfumer and creator of the original CK ONE fragrance, Alberto Morillas crafted the clean and genderless fragrance exuding freshness using 77% of naturally derived ingredients.
The CK EVERYONE bottle and packaging were created from recycled materials to honor its purity and simplicity. The ultra-modern transparent glass bottle contains 10% of post-consumer recycled materials and is recyclable with the removal of the pump and the elastic while the folding carton contains 30% of post-consumer recycled materials.
CK EVERYONE is available globally in a 50ml, 100ml, and 200ml, Eau de toilette spray.
About Coty Inc.
Coty is one of the world’s largest beauty companies with an iconic portfolio of brands across fragrance, color cosmetics, hair color and styling, and skin and body care. Coty is the global leader in fragrance, a strong number two in professional hair color & styling, and number three in color cosmetics. Coty’s products are sold in over 150 countries around the world. Coty and its brands are committed to a range of social causes as well as seeking to minimize its impact on the environment.
For additional information about Coty Inc., please visit www.Coty.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200420005792/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom